Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 5/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.51 |
| ▸ | HTR3B | O95264 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088134 | 0.95 | SOS1 (0.56) | SOS1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL3101725 | 0.88 | HTR3E (0.55) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21154013 | 0.84 | NPC1 (0.50) | SOS1GPR119PIK3CGKDM4EKMT2A | |
| SCHEMBL3082150 | 0.83 | PTGES (0.53) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31349365 | 0.82 | HTR6 (0.52) | HTR6GPR119KDM4EKMT2A | |
| SCHEMBL8513477 | 0.82 | HTR6 (0.52) | SOS1HTR6GPR119 | |
| SCHEMBL5089961 | 0.80 | SOS1 (0.45) | SOS1HTR6GPR119PIK3CGPTGES | |
| SCHEMBL24462170 | 0.80 | PTGES (0.49) | SOS1HTR3APIK3CGHRH4PTGES | |
| SCHEMBL30169682 | 0.80 | HTR6 (0.50) | SOS1HTR6GPR119LMNAHRH4 | |
| SCHEMBL24883385 | 0.80 | HTR6 (0.50) | SOS1HTR6GPR119LMNAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2643318-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | Pierre Fabre Médicament (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| EP-2167490-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Korea Research Institute Of Chemical Technology (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153325-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | SOS1 905/4885HTR6 929/4885HTR3E 619/4885 |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | SOS1 905/4885HTR6 929/4885HTR3E 619/4885 |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CYP51A1, ERG28, CYP3A7 | SOS1 1531/4885HTR6 4167/4885HTR3E 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.